Pulmonary Arterial Hypertension (PAH) Market (Pipeline Analysis: Early-stage Drug Candidates [Phase I & Phase II] and Late-stage Drug Candidates [Phase III & Registration Phase]; and Drug Class: Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists [ERAs], Phosphodiesterase-5 [PDE-5] Inhibitors, and Soluble Guanylate Cyclase [sGC] Stimulators)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Pulmonary Arterial Hypertension (PAH) market size was estimated at USD 6.9 billion in 2021 and is expected to surpass around USD 15.5 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.4% during the forecast period 2022 to 2030. Increase in initiatives by key players, higher cases of pulmonary arterial hypertension, rise in adoption rate, availability of reimbursement, and entry of generics are projected to drive the global market during the forecast period.

Increase in Collaborations for Development of Novel Products: Key Driver

• Focus on collaborations & mergers by leading players to develop innovative products is anticipated to boost the growth of the global market during the forecast period. In 2017, Bayer AG and Vectura Group plc extended their collaboration to develop an upgraded version of nebulizer Breelib that improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. According to the National Institutes of Health, the nebulizer is still in clinical trial and the study was finished in March 2021.
• In September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. This research was conducted by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.

Report Scope of the Pulmonary Arterial Hypertension (PAH) Market

Increase in Awareness about Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high-growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe.

Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.

Rapid Growth in Geriatric Population to Fuel Market Expansion

The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years.

Technological Advancements and Approval of New Drugs to Drive Global Market

Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the pulmonary arterial hypertension (PAH) market. Based on drug class, the global pulmonary arterial hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category.

Promising Drug Pipeline to Boost Market in North America

Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth.

Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players.

Side Effects Associated with PAH Drugs: Key Restraint

• Side effects associated with PAH drugs are likely to hamper the growth of the global market. Vasodilators are primarily prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels.
• According to studies, vasodilators have a number of side effects including edema, heart palpitations, tachycardia, and chest pain. Due to the substantial side effects associated with the use of vasodilators among chronically ill patients, the U.S. FDA regulates the use of this drug.
• Moreover, manufacturers of PAH drugs that treat high blood pressure and dilate blood vessels are required to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercialization.
• The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the usage of PAH drugs are projected to restrain the global market during the forecast period.

Some of the prominent players in the Pulmonary Arterial Hypertension (PAH) Market include:

• Actelion Pharmaceuticals Ltd.
• Gilead Sciences Inc.
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novartis International AG
• Bayer HealthCare
• United Therapeutics Corp
• Other prominent players

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Pulmonary Arterial Hypertension (PAH) market

• Drug Class
• Prostacyclin & Prostacyclin Analogs
• Endothelin Receptor Antagonists (ERAs)
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators
• Pipeline Analysis
• Early-stage Drug Candidates (Phase I & Phase II)
• Late-stage Drug Candidates (Phase III & Registration Phase)

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Pulmonary Arterial Hypertension (PAH) industry analysis from 2022 to 2030 to identify the prevailing Pulmonary Arterial Hypertension (PAH) industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Pulmonary Arterial Hypertension (PAH) industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Pulmonary Arterial Hypertension (PAH) industry trends, key players, market segments, application areas, and market growth strategies.